<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="206491">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400426</url>
  </required_header>
  <id_info>
    <org_study_id>DAHANCA 20</org_study_id>
    <nct_id>NCT00400426</nct_id>
  </id_info>
  <brief_title>DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer</brief_title>
  <official_title>DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Head and Neck Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <brief_summary>
    <textblock>
      Palliative radiotherapy for head and neck cancer is widely used but the effect and side
      effects are largely unknown. We will study the effect of short hypofractionated palliative
      radiotherapy (20 Gy in 4 fractions) on symptom intensity and -frequency as weel as side
      effects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and intensity of symptoms before and after radiotherapy (EORTC C30 and H&amp;N35 questionnaires and CTC AE 3.0 toxicity scores)</measure>
    <time_frame>11 mths</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>11 mths</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>2 mths</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other treatments</measure>
    <time_frame>11 mths</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Recurrence</condition>
  <condition>Neoplasms, Second Primary</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>20 Gy in 4 fx</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Incurable primary or second primary head and neck cancer

          -  Speaks and reads Danish

          -  Capable of filling out questionnaires for at leas two months after radiotherapy

          -  Age&gt;=18 years

          -  Expected survival&gt; 3months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DAHANCA (Danish Head and Neck Cancer Group)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology</name>
      <address>
        <city>Aarhus</city>
        <zip>8000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.DAHANCA.dk</url>
  </link>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 18, 2013</lastchanged_date>
  <firstreceived_date>November 15, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Kenneth Jensen</investigator_full_name>
    <investigator_title>MD ph.d.</investigator_title>
  </responsible_party>
  <keyword>Palliative radiotherapy</keyword>
  <keyword>Recurrent</keyword>
  <keyword>Head and neck Neoplasm</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
